Skip to Content

The Cooper Companies Inc COO

Morningstar Rating
$97.25 +0.45 (0.46%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

COO is trading at a 356% premium.
Price
$96.76
Fair Value
$17.00
Uncertainty
Medium
1-Star Price
$427.70
5-Star Price
$87.50
Economic Moat
Ymrcxn
Capital Allocation
Qlxmcsvv

Bulls Say, Bears Say

Bulls

Cooper is one of the leading vision care companies in the world with a proven track record of successful product development and it will continue to launch technically superior products over the long term.

Bears

While the contact lens market share has been stable, lagging research and innovation from Cooper could start to chip away at the company’s presence in the space.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$96.80
Day Range
$95.4997.25
52-Week Range
$76.02104.07
Bid/Ask
$97.19 / $97.29
Market Cap
$19.32 Bil
Volume/Avg
276,185 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
29.10
Price/Sales
5.27
Dividend Yield (Trailing)
< 0.01%
Dividend Yield (Forward)
0.02%
Total Yield
< 0.01%

Company Profile

The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Core
Total Number of Employees
15,000

Competitors

Valuation

Metric
COO
JNJ
Price/Earnings (Normalized)
29.1014.75
Price/Book Value
2.505.30
Price/Sales
5.274.33
Price/Cash Flow
22.3416.67
Price/Earnings
COO
JNJ

Financial Strength

Metric
COO
JNJ
Quick Ratio
0.810.84
Current Ratio
1.861.17
Interest Coverage
4.7723.57
Quick Ratio
COO
JNJ

Profitability

Metric
COO
JNJ
Return on Assets (Normalized)
2.49%12.64%
Return on Equity (Normalized)
3.88%31.72%
Return on Invested Capital (Normalized)
3.63%20.11%
Return on Assets
COO
JNJ
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncRxcryfjqmGjx$141.9 Bil
BDX
Becton Dickinson & CoJfngjpysBfzgjxw$68.5 Bil
ALC
Alcon IncQhkwxxrdRdsrf$43.5 Bil
RMD
ResMed IncPnhwmwgscTmnlzp$32.1 Bil
CLPBY
Coloplast A/S ADRSqlzshsshkLmbhp$28.0 Bil
WST
West Pharmaceutical Services IncStghzxwzcKbdy$26.0 Bil
BAX
Baxter International IncGrbbbshwDyjxb$17.8 Bil
HOLX
Hologic IncSvlfbblqWpvbcf$17.4 Bil
TFX
Teleflex IncKqwzBvzb$10.3 Bil

Sponsor Center